KRAS and colorectal carcinoma: We observed that the MSKCC MSI-CRC cohort also included patients (64/97, 66%) with either a BRAF, NRAS, or KRAS mutation, whereas our MSI-CRC cohort was entirely composed of BRAF/NRAS/KRAS wild-type tumours.